Hongyi Clinical Development Services

Singapore – September 30, 2026 -- Emerald Clinical Trials has appointed Michael Stibilj as Chief Executive Officer, effective October 1, 2026, tasking the 30-year CRO veteran with leading the next phase of growth for a platform that now spans more than 1,000 professionals across 40-plus countries and 70-plus locations.

Stibilj joins from six years as Chief Operating Officer at Novotech

Before Novotech, Stibilj served three years as CEO of PPC Group and spent 22 years at IQVIA in regional and global leadership roles, with operational experience across China, Singapore and Australia.

Appointment follows the acquisition of Hongyi Clinical Development Services

The deal combined Emerald with Hongyi to create a clinical development platform supporting sponsors from first-in-human trials through post-marketing across China, Asia-Pacific, Europe and the Americas.